Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases by Zhou, Weihua et al.
 
Genetically engineered mouse models for functional studies of
SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Zhou, Weihua, Wenyi Wei, and Yi Sun. 2013. Genetically
engineered mouse models for functional studies of SKP1-CUL1-
F-box-protein (SCF) E3 ubiquitin ligases. Cell Research 23(5):
599-619.
Published Version doi:10.1038/cr.2013.44
Accessed February 19, 2015 12:08:20 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11181052
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions




Cell Research (2013) 23:599-619.
© 2013 IBCB, SIBS, CAS    All rights reserved 1001-0602/13  
www.nature.com/cr
Genetically engineered mouse models for functional studies 
of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases
Weihua Zhou
1, 2, Wenyi Wei
3, Yi Sun
1
1Division of Radiation and Cancer Biology, Department of Radiation Oncology, University of Michigan, 4424B Medical Science-I, 
1301 Catherine Street, Ann Arbor, MI 48109, USA; 
2Department of Oncology, the Second Affiliated Hospital of Nanchang Univer-
sity, 1 Minde Road, Nanchang, Jiangxi 330006, China; 
3Department of Pathology, Beth Israel Deaconess Medical Center, Harvard 
Medical School, Boston, MA 02215, USA
The SCF (SKP1 (S-phase-kinase-associated protein 1), Cullin-1, F-box protein) E3 ubiquitin ligases, the founding 
member of Cullin-RING ligases (CRLs), are the largest family of E3 ubiquitin ligases in mammals. Each individual 
SCF E3 ligase consists of one adaptor protein SKP1, one scaffold protein cullin-1 (the first family member of the eight 
cullins), one F-box protein out of 69 family members, and one out of two RING (Really Interesting New Gene) family 
proteins RBX1/ROC1 or RBX2/ROC2/SAG/RNF7. Various combinations of these four components construct a large 
number of SCF E3s that promote the degradation of many key regulatory proteins in cell-context, temporally, and 
spatially dependent manners, thus controlling precisely numerous important cellular processes, including cell cycle 
progression, apoptosis, gene transcription, signal transduction, DNA replication, maintenance of genome integrity, 
and tumorigenesis. To understand how the SCF E3 ligases regulate these cellular processes and embryonic develop-
ment under in vivo physiological conditions, a number of mouse models with transgenic (Tg) expression or targeted 
deletion of components of SCF have been established and characterized. In this review, we will provide a brief intro-
duction to the ubiquitin-proteasome system (UPS) and the SCF E3 ubiquitin ligases, followed by a comprehensive 
overview on the existing Tg and knockout (KO) mouse models of the SCF E3s, and discuss the role of each compo-
nent in mouse embryogenesis, cell proliferation, apoptosis, carcinogenesis, as well as other pathogenic processes asso-
ciated with human diseases. We will end with a brief discussion on the future directions of this research area and the 
potential applications of the knowledge gained to more effective therapeutic interventions of human diseases.
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The ubiquitin-proteasome system (UPS) fulﬁlls es-
sential cellular functions in eukaryotes through timely 
degradation of a variety of regulatory proteins [1]. The 
UPS-targeted protein degradation involves two well-
defined steps: (1) the covalent attachment of multiple 
ubiquitin molecules to a substrate and (2) the recognition 
and degradation of ubiquitin-tagged substrate by the 26S 
proteasome [2, 3]. Covalent conjugation of ubiquitin to 
the substrate, a process called ubiquitylation, is carried 
out by a three-step enzymatic cascade, involving the E1 
ubiquitin-activating enzyme, E2 ubiquitin-conjugating 
enzyme, and E3 ubiquitin ligase [4] (Figure 1). The sub-
strate speciﬁcity of ubiquitylation is determined by the 
E3 enzymes that directly bind to the target substrates [5]. 
E3 ubiquitin ligases can be further divided into four ma-
jor classes: HECT (Homologous to E6-AP C-terminus) 
domain-containing E3s, RING (Really Interesting New 
Gene) ﬁnger-containing E3s, N-end rule E3s, and APC/
C (Anaphase-Promoting Complex/Cyclosome) E3s [4, 
6]. Whereas the HECT catalytic domain forms an E3-
ubiquitin thioester intermediate prior to transferring the 
ubiquitin to the bound substrate [4, 7], the RING E3s use 
a RING ﬁnger domain to recruit ubiquitin-loaded E2 and 
transfer the ubiquitin from the E2 to a lysine residue on 
a targeted substrate via an isopeptide bond [8]. Ubiqui-
tin has seven lysine residues (K6, K11, K27, K29, K33, Mouse knockout models for SCF E3 ubiquitin ligases
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K48, and K63), and can be further conjugated by another 
ubiquitin to form polyubiquitin chains with distinct 
linkages. As shown in Figure 1, the tagged substrates 
destined for proteasome-mediated degradation usually 
have a K48-linked polyubiquitin chain, which are rec-
ognized by 26S proteasomes for targeted degradation [4, 
9], whereas K63-linked polyubiquitin chains have been 
strongly implicated in regulating various proteasome-in-
dependent cellular functions, including NF-κB signaling 
[10], ribosomal function [11], DNA replication and re-
pair [12], and intracellular trafﬁcking [13]. Furthermore, 
a substrate protein can also be conjugated with just a 
single ubiquitin, a process known as monoubiquitylation, 
which modulates various biological functions [14]. 
The Cullin-RING ligase (CRL) is the largest fam-
ily of E3 ubiquitin ligases with eight family members, 
designated as CRL-1, CRL-2, CRL-3, CRL-4A, CRL-
4B, CRL-5, CRL-7, and the much less known CRL-
9, also designated as PARC (p53-associated parkin-like 
cytoplasmic protein) [6, 15-17]. Each family member 
of CRL E3s consists of a scaffold protein cullin (eight 
family members), an adaptor protein (many family 
members), a RING protein (two family members), and 
a substrate receptor protein (many family members) (for 
review, see [6]) (Figure 2). The SCF E3 ubiquitin ligase, 
also designated as CRL-1, is the founding member of 
CRL E3. The SCF, consisting of SKP1 (S-phase-kinase-
associated protein 1), Cullin-1/Cdc53, and an F-Box 
protein, was ﬁrst deﬁned by two independent groups in 
1996-1997 [18-20]. Subsequent work published in 1999 
from several laboratories revealed that a fully active 
SCF E3 requires a RING protein, RBX1/ROC1 (RING 
box protein 1/regulator of cullins 1) [21-24] or its fam-
ily member, RBX2/ROC2/SAG (Sensitive to Apoptosis 
Gene) [25, 26]. Within the SCF E3 ligases, the cullin 
subunit cullin-1 (Cul-1) functions as a molecular scaf-
fold that simultaneously interacts at its N-terminus with 
the SKP1-F-box complex, and at its C-terminus with 
RBX1 or RBX2, which binds to the ubiquitin-loaded E2 
protein [27] (Figure 2A). The F-box proteins, by binding 
to SKP1 and cullin-1 through the F-box domain, and to 
substrates through their WD40 or leucine-rich repeats 
(LRRs) domains, determine the substrate specificity of 
the SCF complex [27, 28]. The cullin-1-RBX1 or cullin-
1-RBX2 complex, with RBX1/2 binding to ubiquitin-
loaded E2, constitutes the core E3 ligase activity [29]. 
By promoting timely ubiquitylation and subsequent deg-
radation of more than 350 substrates [30], the SCF E3 li-
gases have vital roles in the maintenance of the integrity 
of basic cellular processes, including signal transduction, 
gene transcription, DNA replication and repair, develop-
ment, cell cycle progression, and preservation of genome 
stability [31, 32]. 
Over the past 13 years, a number of transgenic (Tg) 
and knockout (KO) mouse models have been established 
for key components of the SCF E3 complexes. Here, 
Figure 1 The ubiquitin-proteasome system. Ubiquitin (Ub) is first activated in an ATP-dependent reaction by the E1 ubiquitin-
activating enzyme, and transferred to the E2 ubiquitin-conjugating enzyme, and finally transferred to the substrate with the 
help of an E3 ubiquitin ligase, which binds both the substrate protein and the ubiquitin-charged E2 enzyme, resulting in the 
mono-, or polyubiquitylation of the substrate. The mode of ubiquitylation and ubiquitin linkage determine the fate of the sub-
strate: either being modified with altered function (mono-ubiquitylation or K63-linked polyubiquitylation) or being degraded (for 
K48 linkage) by the 26S proteasome, which consists of catalytic 20S and regulatory 19S subunits.www.cell-research.com | Cell Research
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we provide a comprehensive review of the existing Tg 
and KO mouse models of the SCF E3 components, and 
further discuss how these models have led to our current 
understanding of physiological functions of SCF E3s 
and their mechanisms of action. We will end with a 
discussion of future directions of this research area, and 
the potential applications of these mouse models towards 
understanding various human diseases, particularly 
cancer, which is often associated with alterations of SCF 
E3 ubiquitin ligases [33]. 
S-phase kinase-associated protein 1 (SKP1)
SKP1 was ﬁrst identiﬁed in 1995 as one of two essen-
tial elements of the cyclin A-CDK2 S-phase kinase [34], 
and later found to promote ubiquitylation and degrada-
tion of various cell cycle regulators [20]. SKP1 functions 
as an adaptor protein that links Cul-1/Cdc53 and the F-
box protein to form the SKP1-cullin 1-F-box protein 
ubiquitin ligases [15, 17]. In yeast, however, several non-
SCF functions of Skp1 have been reported with Skp1 in-
volvement in recycling of internalized proteins [35], and 
in regulation of cytokinesis and cell division [36]. 
At the present time, no Skp1 KO mouse model is 
available. One group, however, generated Tg mice ex-
pressing a Cul-1 deletion mutant (Cul1-N252), which 
is capable of sequestrating and inactivating Skp1 [37]. 
When expressed in the T-cell lineage, Cul1-N252 causes 
hypoplasia and reduced proliferation in the lymphoid 
organs. After a latent period, however, the Cul1-N252 Tg 
mice develop T-cell lymphomas with high penetrance. 
Importantly, T-cell depletion and subsequent lymphoma 
formation can be largely rescued in Cul1-N252, Skp1 
double Tg mice, indicating that sequestration and inac-
tivation of endogenous Skp1 has a causal role [37]. Fur-
thermore, lymphomas developed in Cul1-N252 Tg mice 
showed remarkable karyotype heterogeneity associated 
with c-Myc overexpression. These results suggest a key 
role for Skp1 in the maintenance of genomic stability 
and euploidy to prevent neoplastic transformation [37]. 
Figure 2 Schematic illustration of CRLs. (A) CRL-1, also known as SCF, is assembled together by a scaffold protein cullin-1, 
which binds at the N-terminus the adaptor protein SKP1 and an F-box protein, and at the C-terminus a RING protein RBX1 
or RBX2/SAG that interacts with the ubiquitin-loaded E2. Generally, most targeted substrates have to be phosphorylated by 
a kinase(s) before being recognized by an F-box protein. SCF E3, whose activity requires cullin-1 neddylation, catalyzes the 
ubiquitin transfer from the E2 to the phosphorylated substrate. (B) CRL-2 consists of cullin-2, RBX1, adaptor proteins Elon-
gin B/C and the substrate receptor VHL. (C) CRL-3 consists of cullin-3, RBX1, and the substrate receptor BTB (Bric-a-brac, 
Tram-track, Broad-complex domain). (D) CRL-4A/B consists of the cullin-4A or cullin-4B, RBX1, adaptor protein DDB1 (DNA 
damage-binding protein 1), and the substrate receptor DCAF (DDB1-CUL4-associated factor). (E) CRL-5 consists of cullin-5, 
RBX2, adaptor proteins Elongin B/C, and the substrate receptor SOCS. (F) CRL-7 consists of cullin-7, RBX1, adaptor protein 
Skp1, and the substrate receptor FBXW8.Mouse knockout models for SCF E3 ubiquitin ligases
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Interestingly, a recent study showed that expression of 
SKP1A (p19, S-phase kinase-associated protein 1A) is 
significantly reduced in sporadic Parkinson’s disease 
[38]. RNAi-mediated silencing of SKP1A in neuronal 
cells increases susceptibility to cell death, whereas intra-
nigral stereotaxic injection of a lentiviral vector targeting 
SKP1A induces pathological and behavioral deficits in 
mice [38]. Thus, establishment of a conditional Skp1 KO 
mouse model with targeted neuronal deletion of Skp1 
may provide an in vivo animal model to study this type 
of Parkinson’s disease. 
Cullins
The cullin family of proteins was first identified in 
1996 as being required for cell cycle exit in C. elegans 
[39] and for the G1-to-S-phase transition in budding 
yeast [40]. The family members are characterized by an 
evolutionarily conserved cullin-homology domain, and 
serve as molecular scaffolds to facilitate the assembly 
of multimeric CRLs with SCF/CRL-1 as the founding 
member. Activity of CRLs requires conjugation of cul-
lins with the ubiquitin-like molecule, NEDD8, a process 
known as cullin neddylation, which induces a conforma-
tional change that increases the proximity between the 
E2 enzyme and the substrates, and prevents the inhibito-
ry association of CAND1 (cullin-associated neddylation-
dissociated protein 1) [41, 42]. Mammalian cullin protein 
family has eight members, including cullin-1, -2, -3, -4A, 
-4B, -5, -7, and -9 [16]. Although among the 8 cullins, 
only cullin-1 is a component of the SCF E3 ligases, this 
review will cover all cullins, with a focus on those for 
which mouse KO models are available. 
Cullin-1
Cul-1 is the most extensively characterized member of 
the cullin family and a key component of SCF E3s (Fig-
ure 2A). To understand the physiological roles of Cul-1 
in mammalian cells, mouse KO studies were performed 
in 1999. Cul-1 KO causes early embryonic lethality at 
E6.5 before the onset of gastrulation. Accumulation of 
cyclin E proteins, but not cyclin E mRNA, was found 
in Cul-1
−/− embryos, blastocytes, and mouse embryonic 
ﬁbroblasts (MEFs), along with increased p53 levels and 
apoptosis in the embryonic ectoderm [43, 44]. Thus, Cul-
1 has an indispensable role in both cell cycle progression 
and early embryogenesis, and cyclin E is a physiological 
substrate of SCF E3. Unfortunately, neither study con-
ducted the rescue experiment by simultaneous deletion 
of cyclin E to determine whether accumulated cyclin E 
is causally related to the embryonic lethality phenotype. 
Nevertheless, the embryonic lethal phenotype of Cul-1 
total KO calls for the necessity of a future conditional 
KO mouse model to study the organ-speciﬁc role of Cul-
1 in development and diseases such as cancer, as Cul-1 
is overexpressed in 40% of lung cancers [45], as well as 
during human melanomagenesis [46].
Cullin-3
Cul-3 forms a complex with RBX1 and BTB (bric-
a-brac, tramtrack, broad-complex domain) proteins (as 
substrate receptors) to constitute an active CRL-3 [16] 
(Figure 2C). Interestingly, Cul-3, but not Cul-1, binds 
to free cyclin E in mammalian cells and is important 
for the ubiquitylation and degradation of free cyclin E 
[47]. More importantly, this study generated a Cul-3 KO 
mouse model to further deﬁne the in vivo physiological 
role of Cul-3. Like Cul-1 KO, Cul-3 KO in mice also 
causes an early embryonic lethal phenotype at E6.5-
7.5 with marked accumulation of cyclin E proteins in 
the extraembryonic ectoderm and in the trophectoderm. 
Cul-3
−/− cells in the extraembryonic ectoderm undergo a 
standard mitotic cell cycle, whereas Cul-3
−/− cells in the 
trophectoderm are blocked from S-phase entry, indicat-
ing a cell-type-speciﬁc effect of Cul-3 on S-phase regu-
lation [47]. Again, this study demonstrated that Cul-3 is 
required for mouse embryogenesis and that cyclin E is a 
physiological substrate of Cul-3-based E3 ligase. How-
ever, the causal relationship between cyclin E accumula-
tion and early embryonic lethality was not determined by 
an in vivo rescue experiment.
Several Cul-3 conditional KO mouse models have 
been established to further define the relationship be-
tween Cul-3 and cyclin E as well as the organ-speciﬁc 
role of Cul-3. Cul-3
−/− MEFs show increased cyclin E 
levels and reduced cell viability. Liver-speciﬁc deletion 
of Cul-3 causes a dramatic increase in cyclin E levels, 
along with an increase in cell size and ploidy, indicat-
ing that Cul-3-based E3 ligases promote the constitutive 
degradation of cyclin E, which is essential for the main-
tenance of the quiescent status of mammalian cells [48]. 
In a more recent study, the same group revealed a poten-
tial role of Cul-3 in liver progenitor and stem cells [49]. 
The liver-specific deletion of Cul-3 causes a persistent 
and massive expansion of hepatic progenitor cells, which 
upon differentiation undergo remarkable DNA damage, 
thereby leading to a cellular senescence response and cell 
death. This process appears to be controlled by p53, as 
simultaneous loss of Cul-3 and p53 in hepatic progeni-
tors transforms these cells to highly malignant tumor-ini-
tiating cells that form largely undifferentiated tumors in 
nude mice. More signiﬁcantly, loss of Cul-3 and p53 re-
sults in the formation of primary hepatocellular carcino-
mas in these mice. Thus, Cul-3 expression during hepatic www.cell-research.com | Cell Research
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differentiation appears to have a safeguard role against 
the formation of tumor-prone progenitor cells [49]. Con-
sistent with this notion, loss of Cul-3 expression was 
observed in a large portion of human liver cancers and 
directly correlated with tumor dedifferentiation [49]. 
Furthermore, a recent study revealed that Cul-3 binds to 
the promyelocytic leukemia zinc ﬁnger (PLZF) transcrip-
tion factor and BCL6 transcription factor, respectively 
[50]. The T cell-speciﬁc (driven by CD4-Cre) or B cell-
speciﬁc (driven by CD19-Cre) Cul-3 KO studies showed 
that Cul-3 likely directs the differentiation of several T- 
and B-cell effector programs and may be involved in the 
oncogenic role of PLZF and BCL6 in the development 
of leukemias and lymphomas, respectively [50]. Finally, 
it is important to note that in human cancers the Cul-3 
adaptor, Keap1, is frequently mutated, and its two well-
characterized substrates, Cyclin E and Nrf2, are often 
overexpressed or activated by mutations that disrupt Cul-
3-dependent regulation, further arguing for a critical role 
of the CRL-3 E3 ligase in modulating tumorigenesis 
[51-53]. Given the recent data that Cul-3-KLHL20 is as-
sociated with prostate cancer progression [54] and Cul-3 
overexpression is correlated with breast cancer progres-
sion [55], and that Cul-3 mutations are detected in squa-
mous cell lung cancers [56] as well as cause hyperten-
sion and electrolyte abnormalities in humans [57], the 
tissue-speciﬁc Cul-3 KO mouse models would be useful 
to mechanistically study these human diseases.
Cullin-2 and cullin-5
Cul-2 forms a complex with RBX1, adaptor proteins 
Elongin B/C and the substrate receptor protein von 
Hippel-Lindau (VHL) to construct an active CRL-2 E3 
with HIF-1α [58, 59] as its best known substrate (Figure 
2B), whereas Cul-5 forms a complex with RBX2/SAG, 
adaptor proteins Elongin B/C, and receptor proteins 
SOCS (suppressors of cytokine signaling) to form an ac-
tive CRL-5 E3 [16] (Figure 2E). No KO mouse models 
are currently available for these two cullins to under-
stand their in vivo physiological functions. However, it 
is anticipated that total KO of either Cul-2 or Cul-5 may 
cause embryonic lethality, given the fact that CRL-2 and 
CRL-5 promote, respectively, the ubiquitylation and deg-
radation of important proteins such as HIF-1α [58, 59] or 
SRC [60] along with many other substrates (for reviews, 
see [6, 61, 62]). Nevertheless, conditional tissue-speciﬁc 
KO mouse models should be generated for these two 
cullins to study their organ-speciﬁc functions. The Cul-2 
conditional KO mouse model may also be useful to study 
colon tumorigenesis, as somatic mutations of Cul-2 were 
detected in a fraction of human colon cancers [63].
Cullin-4A and cullin-4B
In mammalian cells, Cul-4 is encoded by two closely 
related genes, Cul-4A and Cul-4B, which share about 
82% sequence identity with redundant functions [64, 
65]. Cul-4A or Cul-4B can each form a complex with the 
adaptor protein DDB1 (DNA damage-binding protein 1) 
and the substrate receptor protein DCAF (DDB1-CUL-
4-associated factor) to constitute an active CRL-4A or 
CRL-4B E3 (Figure 2D). An early Cul-4a KO study us-
ing the Cre/loxP strategy to ablate exon 1 of the Cul-4a 
gene showed that Cul-4a deletion in Cul-4b wild-type 
background causes embryonic lethality at E7.5, suggest-
ing that Cul-4a is essential to early embryogenesis, and 
that Cul-4a and Cul-4b are functionally non-redundant 
[66]. However, a later study by another group showed 
that germline deletion of exons 17-19 of Cul-4a (dele-
tion of the cullin homology domain, thus abrogating 
Rbx1 binding) has no effect on embryonic development. 
Mice were born alive and healthy without developmental 
abnormalities [65]. The discrepancy between these two 
studies can be explained by the inadvertent ablation of 
a 529-base pair region upstream of the ﬁrst exon of the 
Pcid2 gene that resides on the complementary strand ad-
jacent to Cul-4a exon 1 and encodes an uncharacterized 
protein with homology to essential proteasome subunits 
[65]. The later study also showed that skin-speciﬁc dele-
tion of Cul-4a causes remarkably enhanced resistance to 
UVB-induced skin carcinogenesis. This is likely attribut-
able to the accumulation, upon Cul-4a deletion, of both 
DDB2 and XPC DNA-damage sensors, as well as the 
p21 damage checkpoint effector, leading to an enhanced 
activity of the global genomic repair pathway and rein-
forced UV-responsive G1 DNA-damage checkpoint [65]. 
Thus, although Cul-4a and Cul-4b appear to be function-
ally redundant during embryogenesis, Cul-4a does play 
a critical role in establishing the cellular DNA repair 
threshold, a function not shared by Cul-4b. Furthermore, 
Cul-4a appears to regulate both cell proliferation and 
genome stability, as demonstrated by yet another study 
in which Cul-4a was inactivated via targeted deletion of 
its exons 4-8 (encoding the N-terminal DDB1-binding 
domain) [67]. In that study, Cul-4a
−/− cells were found 
to exhibit deregulated p53 and p27 expression with se-
vere deﬁciency in cell proliferation and signs of genomic 
instability [67], although Cul-4a
−/− mice are alive and 
healthy [64]. Finally, two recent studies showed that 
Cul-4a deletion (at exons 17-19 or 4-8) affects male (but 
not female) fertility and causes severe deficiencies in 
spermatogenesis with increased apoptosis in the testes, 
which is associated with elevated levels of phospho-p53 
and Cdt1 [68, 69]. Yin et al. [69] showed that the repro-
ductive defects in Cul-4a
−/− males largely resulted from Mouse knockout models for SCF E3 ubiquitin ligases
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the distinct and non-overlapping expression patterns of 
the two Cul-4 genes in different stages, which led to the 
meiotic arrest at the pachytene to diplotene stage and 
defects in resolving meiotic chromosomal crossover in 
spermatocytes. These studies revealed a possible indis-
pensable function for Cul-4a during the meiosis of male 
germ cells. 
Most recently, two groups reported Cul-4b KO studies 
[70, 71]. One study with targeted deletion of the exons 
3-5 of Cul-4b showed that Cul-4b
−/− embryos exhibit 
severe developmental arrest and die before E9.5 with 
cyclin E accumulation [70]. Even heterozygous deletion 
of Cul-4b resulted in severe developmental delay with 
disorganized vascularization in placentas. The authors 
concluded that Cul-4b is indispensable for embryonic 
development in mouse [70]. In another study, the exons 
4-5 of Cul-4b, which encode the DDB1-binding domain 
of Cul-4b, were targeted [71]. With the chicken-actin, 
Cre, which causes Cul-4b deletion in both the embryo 
proper and extra-embryonic tissues, the authors observed 
embryonic lethality at E7.5. However, when Cul-4b was 
deleted in the epiblast using the Sox2-Cre (targeted Cul-
4b deletion in the embryo proper only), viable Cul-4b
−/− 
mice were produced likely due to the possible compensa-
tion effect of Cul-4a. Thus, Cul-4b is essential for the de-
velopment of extra-embryonic tissues, which lack Cul-4a 
expression, but is dispensable for embryogenesis itself 
[71]. Given the fact that the Cul-4A gene is ampliﬁed or 
overexpressed in a number of human cancers (for review 
see [61, 72]), which is associated with poor prognosis for 
cancer patients [73], whereas Cul-4B mutations are asso-
ciated with human X-linked mental retardation (XLMR) 
syndrome [74, 75], these Cul-4 conditional mouse mod-
els will be very useful for cancer research (Cul-4a) as 
well as for the study of neuronal and behavioral deﬁcien-
cies seen in human Cul-4B XLMR patients (Cul-4b) [76]. 
Along this line, a conditional Cre-dependent gain-of-
function Cul-4a Tg mouse model has been established 
[77], which can be particularly useful for determining a 
potential causal role of Cul-4a overexpression in diseas-
es, as seen in many human cancers [61, 72], especially in 
organ-speciﬁc tumorigenesis. 
Cullin-7 and cullin-9/PARC
Cul-7 forms a complex with the adaptor protein SKP1, 
RBX1, and the receptor protein FBXW8 to constitute an 
active CRL-7 (Figure 2F), whereas very little is known 
about other components that may bind to Cul-9/Parc to 
form an active CRL-9 [16]. Cul-7
−/− mice die immedi-
ately after birth due to respiratory distress. Vascular de-
fects are seen in both the embryo and placenta, indicating 
a vital role for Cul-7 in cell differentiation and vascular 
morphogenesis [78]. On the other hand, Cul-9/Parc KO 
mice are born at the expected Mendelian ratios and show 
no apparent phenotype, suggesting that the Cul-9 gene 
is dispensable for embryonic development [79]. As Cul-
7 mutations have been found in human 3-M syndrome, 
an autosomal recessive condition characterized by severe 
pre- and post-natal growth retardation [80, 81], and short 
stature syndrome [82], as well as in clear cell renal cell 
carcinomas [83], conditional Cul-7 KO mouse models, if 
generated, may be useful for studying these diseases. 
Figure 3 summarizes the available KO models of cul-
lin family members with a brief description of the KO 
phenotype and accumulated substrates, which likely con-
tribute to the exhibited phenotypes.
Figure 3 Major physiological functions of cullins revealed by genetically engineered mouse models. Among the cullin family 
members, KO mouse models have been generated for Cul-1, Cul-3, Cul-4, Cul-7, and Cul-9, but not yet for Cul-2 and Cul-5. 
Functional consequences of the total or conditional KO of cullins are shown along with the involved substrates and pathways.www.cell-research.com | Cell Research




In the human genome, there are ~69 F-box proteins 
[84], which have been classiﬁed into three categories: (1) 
WD40 domain-containing (FBXWs), (2) LRRs-contain-
ing (FBXLs), and (3) other diverse domains-containing 
(FBXOs) [85, 86]. It is well-established that the F-box 
proteins determine the substrate speciﬁcity of the SCF 
E3s and that a substrate generally has to be phosphory-
lated by a kinase(s) prior to being recognized by an F-
box protein for targeted ubiquitylation and degradation 
[15, 17], with one known exception in which substrates 
are glycosylated before being recognized by Fbx2 [87]. 
To date, only a small fraction of the 69 F-box proteins 
has been characterized with at least one correspond-
ing substrate identified. The list includes β-TrCP1 
(β-transducin repeat-containing protein) (also known as 
FBXW-1), β-TrCP2 (also known as FBXW-11), FBXW-
2, -5, -7, and -8; SKP2 (also known as FBXL-1), FBXL-
3, -5, -6, -12, -20, and -21; and FBXO-2, -3, -4, -6, -7, 
-8, -31, -32, and -33 [88-90]. In this review, we will 
mainly focus on the three best characterized mammali-
an F-box proteins, namely β-TrCP, SKP2, and FBXW7, 
and discuss their in vivo physiological functions re-
vealed through the studies of their respective Tg and/or 
KO mouse models (Figure 4). Available mouse models 
for other F-box proteins will also be described briefly.
Figure 4 Major physiological functions of three well-known F-box proteins revealed by genetically modified mouse models. 
The SCF E3 consists of SKP1, Cul-1, RBX1/SAG and one of 69 F-box proteins that serve as receptors for substrates and 
thereby determine substrate specificity. Among the 69 F-box proteins, β-TrCP, SKP2, and FBXW7 are well-characterized in 
vivo using genetically modified mouse models. Shown are selective substrates that contribute to the KO/Tg phenotypes and 
altered biological processes.Mouse knockout models for SCF E3 ubiquitin ligases
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β-transducin repeat-containing protein (β-TrCP)
Human β-TrCP, first identified in 1998 as a bind-
ing partner of HIV-1 Vpu protein in a yeast two-hybrid 
screening [91], has two family members, namely 
β-TrCP1 (also known as FBXW1, FBW1A, and FWD1) 
and β-TrCP2 (also known as FBXW11, FBW11, FBX-
W1B, FBX1B, and HOS). Human β-TrCP1 and β-TrCP2 
are highly evolutionarily conserved as shown by the 
comparison with their counterparts found in Xenopus 
[92] and Drosophila (known as Slimb) [93]. The β-TrCP 
family member contains a 42-48 amino acid F-box motif 
at the N-terminus for binding to other components of the 
SCF complex and seven WD40 repeats at the C-terminus 
for recognition of substrates, which normally contain the 
conserved DSGxxS motif [94]. Two typical substrates of 
β-TrCP1/2 are IκBα and β-catenin, which are recognized 
after phosphorylation of both serine residues of the DS-
GxxS motif (for reviews see [88, 94]). β-TrCP mainly 
acts as an oncoprotein, but in some situations as a tumor 
suppressor, depending on the function of the targeted 
substrates (for reviews, see [2, 31, 88, 94]) (Figure 4). 
Although β-TrCP1 and β-TrCP2 are biochemically indis-
tinguishable in vitro, it remained unclear before the KO 
studies whether the two β-TrCP paralogues have overlap-
ping functions in vivo or whether each of them recog-
nizes a unique set of substrates. 
Two studies on total β-Trcp1 KO were reported in 
2003 from two independent laboratories. In the first 
study, β-Trcp1 was disrupted by targeted deletion of 
exon 1 (including the translation-initiation site). The 
β-Trcp1
−/− mice are viable and fertile without any ob-
served abnormality up to 16 months [95]. However, 
β-Trcp1
−/− cells (lymphocytes and MEFs) show reduced 
degradation of IκB proteins (IκBα and IκBβ) with cor-
responding inhibition of NF-κB activity. β-Trcp1
 deletion 
also causes accumulation of nuclear, but not cytoplasmic, 
β-catenin in MEFs. Biologically, β-Trcp1 deletion re-
sults in reduced rate of cell proliferation, with increased 
polyploidy [95] and abnormal retinal development [96]. 
In the second study, β-Trcp1 was disrupted with targeted 
deletion of exon 5 (encoding the F-box domain) [97]. 
These β-Trcp1
−/− mice are again viable, but show reduced 
fertility. The corresponding β-Trcp1
−/− MEFs display mi-
totic abnormalities with centrosome overduplication and 
chromosome misalignment. Among known substrates 
of β-Trcp1, accumulation was seen for cyclin A, cyclin 
B, and Emi1, but surprisingly not IκBα and β-catenin, 
whose accumulation requires additional silencing of 
β-Trcp2 by siRNA [97]. Accumulation of Emi1 appears 
to contribute to the moderate impairment in spermato-
genesis and male fertility [97]. These studies clearly sug-
gest that β-Trcp1 and β-Trcp2 are functionally redundant 
during embryonic development as well as in controlling 
the stability of IκBα and β-catenin in vivo. To gain a 
better understanding of β-Trcp redundancy, Kanarek et 
al. [98] recently generated a mouse strain with induc-
ible β-Trcp2 knockdown in combination with β-Trcp1 
KO (designated as KO1/KD2). Even though the β-Trcp2 
level is reduced to only ~10% of the basal level in most 
tissues upon tetracycline treatment, the KO1/KD2 mice 
are still viable and healthy, except for a severe testicular 
defect. The defect is fully reversible upon β-Trcp2 res-
toration and is caused apparently by the accumulation 
of a single β-Trcp substrate, Snail1, as additional deple-
tion of Snail1 completely restored spermatogenesis [98]. 
Detailed analyses performed in this study also suggest a 
non-redundant role of β-Trcp1 and β-Trcp2 in spermato-
genesis. 
Although overexpression and mutations of β-TrCP1 
were reported in multiple human cancers (for reviews, 
see [2, 31, 88, 94]), the causal effect of β-Trcp on tumori-
genesis was best demonstrated using Tg mouse models. 
Whereas mammary glands of β-Trcp1
−/− female mice 
display a hypoplastic phenotype, targeted expression of 
β-Trcp1 by the MMTV promoter in mammary epithelia 
of female mice causes enhanced proliferation with in-
creased NF-κB activity. About 38% of Tg mice develop 
tumors, including mammary, ovarian, and uterine car-
cinomas. In contrast, Tg expression of β-Trcp1 in lym-
phoid organs produces no phenotype, indicating that the   
oncogenic activity of β-Trcp1 is tissue-speciﬁc [99]. In a 
separate study, Tg expression of β-TrCP1 or β-TrCP∆F 
(a dominant-negative mutant with the F-box deleted) in 
intestine, liver, and kidney induces intestinal adenomas 
as well as hepatic and urothelial tumors, likely through 
nuclear accumulation of β-catenin [100].
S-phase kinase-associated protein 2 (SKP2)
SKP2 was ﬁrst identiﬁed in 1995 as the second essen-
tial element of the cyclin A-CDK2 S-phase kinase [34], 
and later found to promote ubiquitylation and degrada-
tion of cell cycle regulators [20]. Many follow-up cell 
culture studies showed that Skp2 promotes proliferation 
and survival of cancer cells in part through targeted deg-
radation of various regulatory substrates, particularly 
tumor suppressors, such as p21, p27, and Foxo1 (for re-
views see [2, 31, 88]) (Figure 4). 
To deﬁne the in vivo physiological function of Skp2, 
a Skp2 total KO mouse model was generated by dele-
tion of exons 1-4 that removes the region from the 
translation-initiation site to the site corresponding to the 
C-terminus of the F-box domain [101]. Skp2
−/− mice are 
viable and fertile, but smaller in size. Skp2
−/− MEFs, as 
well as cells from multiple organs, including liver, lung, www.cell-research.com | Cell Research
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kidney, and testis have enlarged nuclei with polyploidy 
and centrosome overduplication. Furthermore, Skp2
−/− 
MEFs show reduced growth rates and increased apop-
tosis with accumulation of p27 and cyclin E, indicating 
that p27 and cyclin E are in vivo substrates of Skp2 [101]. 
To pursue a causal role of p27 accumulation in the ob-
served phenotype, two independent groups performed in 
vivo rescue experiments [102, 103]. The results showed 
that simultaneous deletion of p27 rescues the defects in 
cell size and ploidy in Skp2
−/− mice, as well as defects in 
cell cycle progression and centrosome overduplication 
in Skp2
−/− cells [102, 103]. These rescue experiments 
demonstrate that p27 is a major physiological target of 
SCF
Skp2, whereas accumulation of cyclin E alone is not 
responsible for the cellular abnormalities of Skp2
−/− mice. 
The Skp2 KO mouse model has also revealed the in-
volvement of Skp2 in the following biological processes 
and/or disease conditions. First, Skp2 regulates the qui-
escence maintenance and self-renewal of hematopoietic 
stem cells (HSCs). Skp2
−/− HSCs show reduced quies-
cence and populate faster than wild-type control cells 
through accelerated cell cycle entry due to increased 
cyclin D1 expression. Moreover, Skp2 loss rescues the 
defect in long-term reconstitution ability of HSCs caused 
by Pten inactivation and sensitizes HSCs to chemothera-
py [104]. Second, Skp2 is required for ovarian develop-
ment. Skp2
−/− female mice show severely compromised 
gamete development from the embryonic stage to follicu-
lar growth in the adult ovary, eventually leading to a de-
creased functional gamete reserve and reduced fertility. 
The defect is caused by p27 accumulation, which can be 
rescued by the simultaneous deletion of p27 [105]. Third, 
Skp2 is also required for proliferation of vascular smooth 
muscle cells. In Skp2
−/− mice, neointima formation is 
retarded compared to wild-type littermates after carotid 
ligation [106]. Fourth, Skp2 controls obesity. Skp2
−/− 
mice had a 50% reduction in both the subcutaneous and 
visceral fat pad mass and adipocyte number, which can 
be completely rescued by p27 deletion [107]. Further-
more, Skp2
−/− mice are more resistant to the development 
of obesity and obesity-related insulin resistance induced 
by a high-fat diet or by the lethal yellow agouti mutation, 
likely due to inhibition of the increase in adipocyte num-
ber [108]. Finally, Skp2
−/− mice are also more resistant to 
nephropathy triggered by unilateral ureteral obstruction 
(UUO), a situation that induces Skp2 expression [109]. 
Moreover, this resistance is abrogated by the simultane-
ous deletion of p27, indicating that p27 accumulation has 
a causal role in the suppression of UUO renal injury [110]. 
Cell culture studies showed that Skp2 typically acts 
as an oncogene by promoting the degradation of many 
tumor suppressors, particularly p27, whereas human 
tissue studies showed Skp2 overexpression in many 
human cancers that is directly associated with poor pa-
tient prognosis (for reviews, see [2, 31, 88]). The causal 
relationship between Skp2 and tumorigenesis has been 
extensively examined using both KO and Tg mouse 
models. A recent in vivo study links Skp2 to cellular se-
nescence induced by oncogenic signals or inactivation of 
tumor suppressors. In response to inactivation of tumor 
suppressors (Arf, Pten), Skp2 deletion triggers a cellular 
senescence response in a manner independent of p19Arf-
p53, but dependent on Atf4/p21/p27. Consequently, Skp2 
deletion reduced the rate of sarcoma/lymphoma forma-
tion and extended the lifespan of Arf
−/− mice. Consis-
tently, Skp2 deletion also inhibits prostate tumorigenesis 
triggered by prostate-speciﬁc Pten loss and extends the 
life-span of these mice [111], and attenuates BCR-ABL-
induced myeloproliferative disease [112]. These studies 
clearly demonstrate that Skp2 is an oncogene or onco-
cooperating gene, and is a promising target for cancer 
prevention and treatment. In another study, Skp2 ablation 
in Rb1
+/− mice blocks spontaneous tumorigenesis in a 
p27-dependent manner, but fails to inhibit tumorigenesis 
induced by a chemical carcinogen, ENU [113]. How-
ever, Skp2 deletion in mice does not signiﬁcantly inhibit 
Myc-driven proliferation and lymphomagenesis [114], 
nor does it affect Myc-mediated tumorigenesis in the 
oral epithelium [115]. The role of Skp2 in proliferation 
and tumorigenesis is further demonstrated in several Tg 
mouse models. Skp2, when targeted to express in the T-
lymphoid lineage, along with activated N-Ras, promotes 
N-Ras-induced T-cell lymphoma formation with shorter 
latency, higher penetrance, and significantly decreased 
survival, indicating a strong N-Ras-cooperative effect 
[116]. Moreover, prostate-specific expression of Skp2 
downregulates p27 and consequently induces hyperpla-
sia, dysplasia, and low-grade carcinoma [117]. Taken 
together, Skp2 appears to be a tissue-speciﬁc oncogene 
or onco-cooperative gene whose deletion suppresses tu-
morigenesis. 
F-box and WD-40 domain protein 7 (Fbxw7)
The ﬁrst member in the gene family of FBXW7 (also 
known as Fbw7, Sel-10, hCdc4, or hAgo) was identiﬁed 
in 1973 in budding yeast by Hartwell et al. [118], desig-
nated as Cdc4 [118]. Human FBXW7 is a well-charac-
terized F-box protein that binds to its substrates through 
a Cdc4 phosphodegron (CPD) consensus motif, IL-I/L/P-
pT-P, that is present on the substrates targeted for protea-
somal degradation [119]. Almost all FBXW7 substrates 
are oncogenic proteins, including c-Myc, c-Jun, cyclin 
E, and Notch (for review, see [119]) with one exception 
which is the tumor suppressor neuroﬁbromatosis type 1 Mouse knockout models for SCF E3 ubiquitin ligases
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(NF1), a physiological substrate of FBXW7 newly iden-
tiﬁed in our laboratory [120]. Functionally, FBXW7 is a 
haploinsufﬁcient tumor suppressor [121] with mutations 
found in many human cancers (for review, see [119]).
The in vivo physiological functions of Fbxw7 dur-
ing embryonic development were characterized by two 
KO studies. Fbxw7 total KO causes embryonic lethality; 
Fbxw7
−/− embryos die in utero around E10.5-11.5 with 
remarkable abnormalities in vascular development in the 
brain and yolk sac, as well as deficient heart chamber 
maturation [122, 123]. These abnormalities are likely as-
sociated with the dysregulation of Notch signaling, along 
with cyclin E accumulation [122, 123], but no genetic 
rescue experiments were conducted to firmly establish 
the causal relationship. A subsequent study showed that 
Fbxw7 is a haploinsufficient tumor suppressor gene, 
as Fbxw7
+/− mice display a greater susceptibility to 
radiation-induced tumorigenesis with the wild-type al-
lele being retained and expressed [121]. Fbxw7
+/− mice 
in the p53
+/− background develop a wide range of tumors 
in epithelial tissue, such as the lung, liver, and ovary. 
MEFs from Fbxw7-deﬁcient mice or with Fbxw7 knock-
down have higher levels of Aurora-A kinase, c-Jun, and 
Notch4, but not of cyclin E. It was proposed that Fbxw7 
acts as a tumor suppressor by maintaining genomic sta-
bility [121].
Studies with lineage- and tissue-speciﬁc KO of Fbxw7 
have revealed its diverse functions. Conditional KO mice 
with ablation of Fbxw7 in the T-cell lineage showed that 
Fbxw7 deﬁciency in immature T cells causes a failure in 
cell cycle exit, leading to thymic hyperplasia and subse-
quent development of thymic lymphoma, in part due to 
the excessive accumulation of c-Myc [124]. Mature T 
cells from Fbxw7
−/− mice, however, fail to proliferate in 
response to mitogenic stimulation, but instead undergo 
apoptosis, which is associated with the accumulation 
of c-Myc and p53, and can be rescued by the additional 
deletion of p53. Thus, Fbxw7 regulates the cell cycle in 
a manner dependent on the differentiation stage [124]. 
Targeted deletion of Fbxw7 in HSCs results in (a) defec-
tive quiescence maintenance, impaired self-renewal, and 
loss of competitive repopulating capacity in one study 
[125], and (b) premature depletion of HSCs and p53-de-
pendent apoptosis in the other report [126]. Furthermore, 
Fbw7 deletion confers a selective advantage to cells 
with suppressed p53 function, leading to the develop-
ment of T-cell acute lymphoblastic leukemia [126]. How 
Fbxw7-deﬁcient cells evade cell death in the setting of 
elevated accumulation of c-Myc remains elusive, but it 
is likely due to the accumulation of Mcl-1, a prosurvival 
protein which has recently been characterized as a novel 
substrate of Fbxw7 [127, 128]. Indeed, increased Mcl-1 
levels were found in thymus tissues, as well as the result-
ing thymic lymphoma and acute lymphoblastic leukemia 
cells from mice with the T-cell lineage-speciﬁc deletion 
of Fbxw7 [124, 127]. 
Other conditional KO studies showed unique func-
tions of Fbxw7 in various organs. For example, Fbxw7 is 
haploinsufﬁcient for intestinal tumor suppression in the 
conditional gut-speciﬁc Fbxw7 KO mice [129]. Liver-
specific Fbxw7 ablation induces abnormalities in lipid 
metabolism and cell differentiation, likely due to the ac-
cumulation of SREBPs and Notch1, respectively [130]. 
Additionally, mice with conditional brain-speciﬁc dele-
tion of Fbxw7 exhibit severely impaired stem cell differ-
entiation and increased progenitor cell death. These mice 
die shortly after birth with morphological abnormalities 
of the brain and the absence of suckling behavior [131, 
132]. Thus, Fbxw7 serves as a key regulator of progeni-
tor cell viability and differentiation of neural stem cells 
in the brain, which is associated with its regulation of 
c-Jun and Notch (Notch1 and Notch 3), respectively 
[131, 132]. It is likely that the tissue-speciﬁc function of 
Fbxw7 is mediated by selective targeting of unique sets 
of Fbxw7 substrates in tissue- and cell context-depen-
dent, and spatially and temporally controlled manners. 
Most importantly, Fbxw7 alterations have been observed 
in many human cancers (for review, see [133]), consis-
tent with the ﬁnding that it is a haploinsufﬁcient tumor 
suppressor in mice. 
Other F-box proteins
(1) Fbxw8 (also known as FBW6, FBW8, FBX29, 
FBXW6, or FBXO29). Fbxw8 forms a complex with 
Cul-7-RBX1-SKP1 to promote degradation of the insu-
lin receptor substrate 1 [134] and cyclin D1 [135], thus 
regulating cell proliferation and survival. Two Fbxw8 
total KO studies were reported. In the ﬁrst study, exon 
2 that encodes the F-box domain was disrupted. About 
two-thirds of Fbxw8
−/− embryos die in utero, whereas the 
remaining one-third are born alive and grow to the adult-
hood. Phenotypically, Fbxw8
−/− embryos show intrauter-
ine growth retardation and abnormal development of the 
placenta [136]. In the second study, a gene-trap approach 
was used with the targeting vector inserted at the 3′ end 
of exon 3 of the Fbxw8. Again, about 30% of Fbxw8
−/− 
mice survived the birth, but these mice remained smaller 
than their wild-type littermates in both body weight and 
organ sizes [137]. Thus, Fbxw8 appears to have a signiﬁ-
cant role in growth control. 
(2) Fbx4 (also known as Fbxo4). Fbx4 binds to αB 
crystallin to assemble an active SCF
FBX4-αB crystallin E3 for 
targeted degradation of cyclin D1, and thus plays in-
portant roles in inhibiting cell cycle progression [138], www.cell-research.com | Cell Research
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suppressing oncogenic transformation [139], and main-
taining genomic stability [140]. Fbx4
−/− mice were gener-
ated to investigate the in vivo tumor suppressor function 
of Fbx4. Whereas Fbx4
−/− mice are viable without major 
developmental defects, Fbx4
−/− MEFs do exhibit cyclin 
D1 accumulation and nuclear localization with increased 
susceptibility to Ras-induced transformation. More im-
portantly, both Fbx4
+/− and Fbx4
−/− mice develop mul-
tiple types of tumors, including lymphomas, histiocytic 
sarcomas and, less frequently, mammary and hepatocel-
lular carcinomas. Finally, a majority of Fbx4 mutations 
identiﬁed in human esophageal tumors are hemizygous 
and occur in the N-terminal regulatory region of FBX4, 
which disrupt ligase dimerization, suggesting that a re-
duction in the Fbx4 dosage and SCF
Fbx4 activity is suf-
ficient to stabilize cyclin D1 and subsequently trigger 
neoplastic growth [139]. Thus, Fbx4 is a bona fide tumor 
suppressor [139, 141]. 
(3) Fbx2 (also known as Fbxo2). Fbx2 binds speciﬁ-
cally to proteins attached to N-linked high-mannose 
oligosaccharides, and targets N-glycosylated proteins 
for ubiquitylation and degradation [87]. A recent study 
showed that Fbx2 promotes the degradation of β-site 
amyloid precursor protein-cleaving enzyme 1 (BACE1), 
leading to the attenuation of Alzheimer’s disease amyloi-
dosis and improvement of synaptic function [142]. Mice 
with targeted deletion of Fbx2 develop accelerated, age-
related hearing loss starting at 2 months. Cellular degen-
eration begins in the epithelial support cells of the organ 
of Corti, whereas progressive degeneration is observed 
in hair cells and the spiral ganglion, but not in the brain 
itself. This study demonstrates that Fbx2 is essential for 
inner ear homeostasis and acts to prevent age-related 
hearing loss [143]. The relationship between the hearing 
loss and potential accumulation of BACE1 or other N-
glycosylated proteins, however, still remains unclear.
(4) Fbxo7 (also known as Fbx7). An early study 
showed that Fbxo7 promotes the degradation of hepato-
ma upregulated protein (HURP) [144]. A Tg mouse mod-
el was established with a LacZ insertion into the Fbxo7 
locus to reduce its expression. Homozygous Fbxo7
LacZ 
mice showed signiﬁcantly increased pro-B cell and pro-
erythroblast populations, consistent with a role of Fbxo7 
in inhibiting proliferation and/or promoting maturation 
of hematopoietic precursor cells [145]. It is, however, 
unknown whether these phenotypic changes have any-
thing to do with HURP.
(5) Fbxl5. FBXL5 contains a unique N-terminal hem-
erythrin-like domain that directly binds to iron. Under 
iron-depleted conditions, FBXL5 is degraded in a man-
ner dependent on this iron-binding domain. Under iron-
replete conditions, however, FBXL5 forms an active E3 
with SKP1-CUL1, and catalyzes the ubiquitylation and 
degradation of iron regulatory protein 2 (IRP2). Thus, 
FBXL5 regulates intracellular iron homeostatsis [146]. 
This function was further conﬁrmed by a recent mouse 
KO study [147]. Fbxl5
−/− mice die in utero with exces-
sive accumulation of iron and IRP2, which is rescued by 
Irp2 ablation. Liver-speciﬁc deletion of Fbxl5 results in 
deregulation of both hepatic and systemic iron homeosta-
sis, and eventually leads to steatohepatitis. Thus, Fbxl5 
plays a major role in controlling an appropriate supply of 
iron to cells via modulating IRP2 levels [147]. 
(6) Fbxo45. Fbxo45 is an F-box protein with restricted 
expression in the nervous system. It fails to bind to Cul-1 
due to an amino acid substitution at the consensus Cul-1 
binding site, but speciﬁcally associates with protein asso-
ciated with Myc (PAM), another RING ﬁnger-type ubiq-
uitin ligase, through its SPRY domain [148]. Fbxo45
−/− 
mice die soon after birth due to respiratory distress, and 
Fbxo45
−/− embryos show abnormal neural development 
[148]. Similar defects are also found in mice lack-
ing Phr1 (the mouse ortholog of PAM), indicating that 
Fbxo45 has an important role in neural development pos-
sibly by forming a novel Fbxo45-PAM ubiquitin ligase 
complex. Although Fbxo45 promotes p73 degradation 
[149], the potential involvement of p73 in its biological 
function is unknown.
(7) Fbx15. Fbx15 is a downstream target of the tran-
scription factor Oct3/4 which is essential for self-renewal 
of ES cells. Homozygous deletion of Fbx15 has no effect 
on embryogenesis in mouse, nor does it affect the cel-
lular morphology or capacity for proliferation and differ-
entiation of mouse embryonic stem (ES) cells, indicating 
that Fbx15 is not an essential gene for embryonic devel-
opment [150].
The RING components, RBX1, and RBX2/SAG
The RING component of SCF E3 ubiquitin ligases is 
composed of two family members, RBX1 and RBX2 [25, 
72]. RBX1, also known as ROC1 or HRT1, was initially 
cloned in 1999 in four different laboratories [21-24]. 
RBX1 consists of five exons and four introns, and en-
codes 108 amino acids with a molecular weight of about 
14 kDa in humans [21-24]. SAG, also known as RBX2 
or ROC2, was originally cloned in our laboratory as a 
redox-inducible antioxidant protein [25], containing four 
exons and three introns with exon 2 spliced out to give 
rise to an open reading frame of 113 amino acids [151, 
152]. Both RBX1/ROC1 and SAG/RBX2/ROC2 contain 
an evolutionarily conserved RING zinc finger domain 
at the C- terminus, which is required for their ubiquitin 
ligase activity [26, 153]. Both RBX1/ROC1 and SAG/Mouse knockout models for SCF E3 ubiquitin ligases
610
npg
 Cell Research | Vol 23 No 5 | May 2013
RBX2/ROC2 are capable of binding to six members of 
the cullin family (Cul1-3, Cul-4A/4B, and Cul-5) under 
overexpressed conditions and show an in vitro E3 ubiq-
uitin ligase activity when forming a complex with Cul-1 
[26, 154]. Before our KO studies, the only known differ-
ence between RBX1 and RBX2 is that RBX1 is consti-
tutively expressed and prefers to bind with Cul-2/VHL, 
whereas SAG is stress-inducible and more selectively 
binds to Cul-5/SOCS [155, 156]. Our recent mouse KO 
studies (see below) revealed that the in vivo functions 
of Rbx1 and Sag are non-redundant during embryonic 
development with each protein potentially targeting dif-
ferent sets of substrates [120, 157].
RBX1/ROC1
RBX1 activates SCF E3 ligase activity by promoting 
cullin-1 neddylation to facilitate the ubiquitin transfer 
from E2 to substrates [158, 159]. To understand the in 
vivo physiological function of RBX1, we attempted to 
generate an Rbx1 KO mouse model via a gene-trap ap-
proach [157]. We found that targeted inactivation of 
Rbx1 caused embryonic lethality at embryonic day E7.5 
due to proliferation failure [157]. Our mechanistic study 
further revealed that Rbx1 inactivation caused signiﬁcant 
accumulation of p27, which is normally not expressed in 
the E6.5 to E7.5 embryos [157]. It is, therefore, conceiv-
able that the accumulated p27 would block cell cycle 
progression to suppress proliferation of the embryos. To 
determine whether p27 accumulation is causally related 
to the embryonic death at E7.5, we performed an in vivo 
rescue experiment and found that simultaneous deletion 
of p27 rescues the early embryonic lethality induced by 
Rbx1 inactivation and extends the embryonic life-span 
from E6.5 to E9.5, indicating that p27-mediated cell cy-
cle inhibition partially contributes to the early lethality in 
Rbx1-deﬁcient embryos [157]. Failure in embryonic res-
cue to full-term by p27 deletion indicates that p27 is no 
longer critical beyond E9.5, or the accumulation of other 
Rbx1-SCF substrates is lethal. Although previous stud-
ies using the yeast as a model revealed that RBX1 and 
RBX2/SAG are interchangeable in rescuing the death 
phenotype caused by ablation of Hrt1 (the only yeast ho-
molog of RBX1/SAG) [22, 23, 26], and the in vitro bio-
chemical assays showed that RBX1 and RBX2/SAG are 
interchangeable in promoting protein polyubiquitylation 
[26, 160], our mouse Rbx1 KO study conducted under 
the Sag
+/+ background provided the ﬁrst demonstration 
that the two RING family members are not functionally 
redundant in vivo during mouse embryogenesis [157]. 
Although the precise underlying mechanism(s) remains 
elusive, it likely involves the preferential binding of 
Rbx1 to Cul-2 vs Rbx2/Sag to Cul-5 [156, 161], result-
ing in the formation of different CRLs (CRL-2 vs CRL-
5) to target unique sets of substrates in a cell context- and 
development stage-dependent manner. Future studies are 
needed to resolve this important issue [62]. 
SAG/RBX2/ROC2
SAG/RBX2/ROC2, the second family member of the 
SCF RING component was ﬁrst cloned in our laboratory 
as a redox-inducible protein [25, 162]. Our subsequent 
work showed that SAG can also be induced by the tumor-
promoting agent 12-O-tetradecanoylphorbol-13-acetate 
(TPA) via activator protein-1 (AP-1) transactivation [155] 
and hypoxia via HIF1 transactivation [163]. Using a cell 
culture-based model, we found that SAG overexpres-
sion inhibits, whereas SAG siRNA knockdown enhances 
TPA-induced neoplastic transformation by targeting c-
Jun, thus modulating AP1 activity [155]. To determine 
the role of SAG in skin tumorigenesis in a more physi-
ological setting, we generated two independent Tg mouse 
lines with targeted SAG expression in epidermis, driven 
by the K14 promoter [164]. Although SAG Tg expres-
sion has no detectable effect on epidermis development 
and proliferation under unstressed conditions, it inhibits 
TPA-induced epidermal proliferation by targeting c-Jun 
for degradation [164]. On the other hand, in UV-induced 
epidermal proliferation, SAG Tg expression promotes 
the degradation of both c-Jun (pro-proliferation) and p27 
(antiproliferation) with a net outcome of enhanced pro-
liferation [165], suggesting a more signiﬁcant role of p27 
in suppression of UVB-induced skin proliferation. 
We next examined the effect of SAG Tg expres-
sion on skin carcinogenesis initiated by DMBA 
[7,12-dimethylbenz(a)-anthracene] and promoted by 
TPA or by UVB exposure. The DMBA/TPA two-stage 
model for skin squamous cell carcinoma (SCC), which 
recapitulates the development of human skin SCC, is 
the most commonly used model [166]. We demonstrated 
that during DMBA/TPA-induced skin carcinogenesis, 
SAG Tg expression caused an early-stage suppression 
of hyperplasia and tumor formation by promoting c-
Jun degradation (in cooperation with Fbxw7), thereby 
inhibiting AP-1, but a later-stage enhancement of tumor 
growth by promoting IκBα degradation (in coopera-
tion with β-TrCP), thus activating NF-κB and inhibiting 
apoptosis [164]. This stage-dependent effect of SAG led 
to a fewer number, but a bigger size of tumors per animal 
in SAG Tg mice, as compared to the non-Tg littermates 
[164]. Using the same SAG Tg mouse model, we found 
that SAG Tg expression promotes skin hyperplasia, but 
not skin tumors induced by UVB exposure. This is likely 
due to SAG-mediated simultaneous degradation of c-Jun 
(oncogenic) and p27 (tumor suppressive), leading to a www.cell-research.com | Cell Research
Weihua Zhou et al.
611
npg
moderate biological outcome [165].
We further pursued physiological functions of Sag 
during embryogenesis by generating Sag KO mice using 
a gene-trap approach [120]. Like Rbx1 disruption, Sag 
disruption also caused embryonic lethality, but at the lat-
er stage of E11.5-12.5, likely due to poor vasculogenesis, 
defective neuronal development, and widespread apop-
tosis [120]. Mechanistic studies using mouse embryonic 
stem (ES) cells revealed that Sag inactivation caused the 
accumulation of Nf1, a well-known tumor suppressor 
that converts GTP-bound active Ras to GDP-bound inac-
tive Ras [167]. Accumulated Nf1 inhibits Ras activity 
and the Ras-MAPK signaling pathway, thus preventing 
ES cells from undergoing endothelial differentiation in 
vitro to form blood island structures (the in vitro version 
of in vivo vasculogenesis), and inhibiting in vivo angio-
genesis and proliferation in teratomas upon injection of 
the mutant ES cells into nude mice [120]. Signiﬁcantly, 
the defect in endothelial differentiation can be fully res-
cued by the simultaneous deletion of even one Nf1 allele, 
which is sufﬁcient to reactivate the Ras-MAPK pathway, 
indicating a causal effect of Nf1 accumulation. Indeed, 
detailed biochemical characterization revealed that SAG, 
in cooperation with FBXW7, promotes NF1 ubiquityla-
tion and degradation; thus NF1 is a novel substrate of the 
SAG-SCF
FBXW7 E3 ligase [120].
Figure 5 The in vivo and in vitro biological functions of the two RING finger proteins, RBX1 and SAG. The RING finger pro-
teins of SCF E3 have two family members, RBX1 and SAG/RBX2. Both are required for mouse embryonic development 
through targeted degradation of p27 (for Rbx1) [157] and Nf1 (for Sag) [120], respectively. Upon induction of RBX1 by mito-
gen [154] and of SAG by UV, TPA or ROS [72], the RING proteins recruit other components of SCF for targeted degradation 
of cognate substrates. SAG Tg expression modulates skin carcinogenesis induced by DMBA/TPA by inhibiting cell prolifera-
tion via targeting c-Jun/AP-1 at the early stage, but promoting tumor growth via targeting IκB to activate NFκB at the later 
stage [164]. SAG transgenic expression also regulates epidermal hyperplasia by targeting p27 and c-Jun [165]. RBX1 also 
likely modulates carcinogenesis in part via regulating apoptosis, autophagy and senescence [171, 172]. MLN4924, a small 
molecule inhibitor of NAE, blocks cullin neddylation to inactivate SCFs, leading to the induction of apoptosis, autophagy and 
senescence [179, 181, 183, 184], thus acting as a novel class of anticancer agent.Mouse knockout models for SCF E3 ubiquitin ligases
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We further determined whether the simultaneous dele-
tion of Nf1 would rescue vascular defects in Sag
−/− em-
bryos and found that Sag
−/−;Nf1
−/− embryos indeed show 
an improved vasculature with reappearance of some 
trunk blood vessels as well as reduced number of apop-
totic cells in the head areas, indicating a partial rescue of 
defects in vasculogenesis and apoptosis [120]. However, 
simultaneous Nf1 deletion failed to extend the embry-
onic life-span of Sag
−/− embryos, indicating that Sag 
substrates other than Nf1 might have a key role in mouse 
embryonic development beyond E12.5. Nevertheless, 
our study clearly demonstrates an in vivo physiological 
function of Sag in regulating vascular and neural devel-
opment through targeted degradation of Nf1 to modulate 
the Ras-MAPK signaling pathway. Furthermore, as this 
Sag KO study was conducted under the Rbx1
+/+ back-
ground, our study further conﬁrmed that Sag and Rbx1 
play a non-redundant roles during mouse embryogenesis. 
Both our in vitro cell culture and in vivo KO studies 
showed that SAG is an anti-apoptotic cellular survival 
protein whose overexpression protects cells from apopto-
sis induced by various stimuli (for review, see [62, 72]), 
whereas its silencing by siRNA or its deletion by gene 
KO induces apoptosis [120, 160, 168]. Consistently, 
SAG was found to be overexpressed in multiple human 
cancer tissues including carcinomas of the lung, colon, 
stomach, and liver [168-170], and SAG overexpression 
correlates with poor survival of lung cancer patients [170]. 
Our unpublished data using a conditional Sag KO mouse 
model showed that Sag is required for lung tumorigen-
esis induced by Kras
G12D. Thus, Sag appears to be an 
onco-cooperating gene whose overexpression is causally 
related to tumorigenesis. 
The results of our in vivo Tg and KO studies, along 
with in vitro cell culture-based studies on RBX1 and 
SAG, are summarized in Figure 5. Both Rbx1 and Sag 
are required for mouse embryonic development and 
play essential roles in regulation of cell proliferation and 
survival as well as carcinogenesis. Inactivation of either 
RBX1 or SAG inhibits carcinogenesis via various mech-
anisms, including apoptosis, senescence, and autophagy 
[168, 171, 172]. Thus, RBX1/SAG and their associated 
SCF E3 ligases have been considered to be attractive an-
ticancer targets [2, 33, 72, 173, 174]. Indeed, MLN4924, 
a newly discovered small molecule inhibitor of NEDD8-
activating enzyme (NAE), which inactivates the SCF/
CRL E3 ligases by blocking cullin neddylation, a process 
required for SCF/CRL E3 activity [175, 176], showed 
impressive anticancer activity by inducing apoptosis 
[176-180], senescence [111, 181, 182], and autophagy 
[183, 184], and is being developed as the first-in-class 
NAE inhibitor for anticancer therapy [185].
Conclusion and future perspectives
The SCF E3 ubiquitin ligases that operate together 
with the upstream E1 and E2 enzymes, and the down-
stream 26S proteasome, have a crucial role in the mainte-
nance of the integrity of many basic cellular processes [15, 
17, 31, 32]. Over the past 15 years, we have achieved a 
better understanding of the functional signiﬁcance of the 
SCF E3 ligases and their associations with human diseas-
es through extensive studies using approaches including 
biochemistry, cell biology, structural biology, genomics, 
proteomics, and genetically modiﬁed mouse models. In 
this review, we provide a comprehensive overview of the 
existing Tg and KO mouse models generated by target-
ing many individual components of the SCF E3 ligases, 
and discuss their biological functions under in vivo phys-
iological settings, which are summarized in Figures 3-5. 
In our opinion, future functional studies of SCF E3 li-
gases using genetically engineered mouse models should 
be extended and directed to the following areas (Figure 6).
 First of all, efforts should be made to generate and 
characterize mouse models that faithfully recapitulate 
the pathological conditions of human diseases. Examples 
include Cul-4b for human XLMR syndrome [74, 75], 
Cul-7 for 3-M syndrome [80, 81], and Fbxo7 for Parkin-
sonian-Pyramidal Disease (PPD) [186, 187]. These mod-
els would be instrumental for the study of the disease 
mechanisms and the development of potential therapeu-
tic interventions.
Second, new mouse models should be established to 
target the remaining components of the SCF E3s, includ-
ing all 69 F-box genes, for tissue-speciﬁc Tg expression 
(gain-of-function) and KO (loss-of-function), ideally 
in an inducible manner. Successful completion of this 
comprehensive study will not only provide us the entire 
picture of physiological functions of SCF E3s, but also 
differentiate overlapping/redundant vs unique functions 
between family members in a tissue-speciﬁc manner. Ex-
amples include Cul-4a vs Cul-4b, β-TrCP1 vs β-TrCP2, 
and Rbx1 vs Sag/Rbx2.
Third, efforts should be made to characterize the 
causal role and contribution of any given substrate to 
the phenotype(s) of SCF E3 KOs. This can be achieved 
through rescue experiments by simultaneous deletion 
of the accumulated substrates, one at a time or in com-
bination of a few if necessary. For example, the embry-
onic death phenotype of Rbx1 KO can only be partially 
rescued by simultaneous p27 deletion. As Cdt1, which 
mediates DNA-damage response and cell killing, is ac-
cumulated upon Rbx1 silencing [188], KO of Cdt1 in 
addition to Rbx1
 and p27 may lead to the full rescue of 
embryonic lethality or further extend the embryonic life-www.cell-research.com | Cell Research
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Figure 6 Outline of future perspectives for studies involving mouse models of the SCF E3s. Four future directions are pro-
posed: (1) human disease-relevant mouse models for disease characterization and intervention; (2) tissue-specific and induc-
ible KO/Tg models of the remaining components of SCF E3s for additional functional studies; (3) rescuing mouse models for 
mechanistic studies; and (4) compound mouse models in combination with dominant oncogenes or loss of tumor-suppressor 
genes for carcinogenesis studies. 
span. Another rescue example would be to KO Noxa, a 
pro-apoptotic protein which is accumulated upon Sag 
silencing [168], in addition to Sag and Nf1, to block the 
widespread apoptosis seen in the Sag
−/− embryos [120].
Finally, the majority of the individual components 
of SCF E3s may not be a bona fide dominant tumor 
suppressor or oncogene by itself, but they may cooper-
ate with dominant oncogenes or tumor suppressors to 
regulate tumorigenesis. Therefore, efforts should be 
made to generate compound mouse models in which 
manipulation of an SCF E3 component is combined with 
an activated oncogene (such as Kras) or an inactivated 
tumor suppressor (such as p53 or Pten loss) to determine 
whether, for example, Rbx1 or Sag, which is frequently 
overexpressed in human cancers [168, 171], indeed plays 
a causal role or their overexpression is just the conse-
quence of tumorigenesis. The information gained from 
these series of future studies would help to justify the use 
of SCF E3 inhibitors, such as MLN4924 [176], which is 
currently in clinical trials [185, 189] for the treatment of 
human cancers with activated SCF E3 ligases.
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